PT3134430T - Proteínas agonistas do recetor de trail de cadeia simples - Google Patents

Proteínas agonistas do recetor de trail de cadeia simples

Info

Publication number
PT3134430T
PT3134430T PT157210899T PT15721089T PT3134430T PT 3134430 T PT3134430 T PT 3134430T PT 157210899 T PT157210899 T PT 157210899T PT 15721089 T PT15721089 T PT 15721089T PT 3134430 T PT3134430 T PT 3134430T
Authority
PT
Portugal
Prior art keywords
receptor agonist
agonist proteins
chain trail
trail
chain
Prior art date
Application number
PT157210899T
Other languages
English (en)
Inventor
Thiemann Meinolf
Hill Oliver
Gieffers Christian
G Buchanan Fritz
C Phillips Darren
E Lappe Susan
Original Assignee
Abbvie Inc
Apogenix Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc, Apogenix Ag filed Critical Abbvie Inc
Publication of PT3134430T publication Critical patent/PT3134430T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
PT157210899T 2014-04-23 2015-04-23 Proteínas agonistas do recetor de trail de cadeia simples PT3134430T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461983152P 2014-04-23 2014-04-23

Publications (1)

Publication Number Publication Date
PT3134430T true PT3134430T (pt) 2018-04-20

Family

ID=53055121

Family Applications (1)

Application Number Title Priority Date Filing Date
PT157210899T PT3134430T (pt) 2014-04-23 2015-04-23 Proteínas agonistas do recetor de trail de cadeia simples

Country Status (37)

Country Link
US (4) US9908927B2 (pt)
EP (2) EP3134430B1 (pt)
JP (2) JP6523331B2 (pt)
KR (2) KR102079919B1 (pt)
CN (2) CN106459221B (pt)
AR (1) AR100168A1 (pt)
AU (3) AU2015249649B2 (pt)
BR (1) BR112016024515B1 (pt)
CA (2) CA3184067A1 (pt)
CL (1) CL2016002683A1 (pt)
CR (1) CR20160516A (pt)
CY (1) CY1120281T1 (pt)
DK (1) DK3134430T3 (pt)
DO (1) DOP2016000284A (pt)
EC (1) ECSP16089579A (pt)
ES (1) ES2672368T3 (pt)
HR (1) HRP20180950T1 (pt)
HU (1) HUE038914T2 (pt)
IL (2) IL248244B (pt)
LT (1) LT3134430T (pt)
MA (2) MA39770A (pt)
MX (2) MX2016013858A (pt)
MY (1) MY181986A (pt)
NO (1) NO2776305T3 (pt)
PE (1) PE20170299A1 (pt)
PH (1) PH12016502079B1 (pt)
PL (1) PL3134430T3 (pt)
PT (1) PT3134430T (pt)
RS (1) RS57153B1 (pt)
RU (1) RU2699285C2 (pt)
SG (3) SG10201806465TA (pt)
SI (1) SI3134430T1 (pt)
TR (1) TR201806912T4 (pt)
TW (2) TWI747178B (pt)
UA (1) UA118286C2 (pt)
UY (1) UY36095A (pt)
WO (1) WO2015164588A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107709355B (zh) * 2015-05-04 2021-09-14 阿珀吉尼科斯股份公司 单链cd40受体激动剂蛋白
AU2016342420B2 (en) * 2015-10-23 2020-10-01 Apogenix Ag Single-chain LIGHT receptor agonist proteins
AU2016341402B2 (en) * 2015-10-23 2020-08-27 Apogenix Ag Single-chain GITR-receptor agonist proteins
AU2016341409B2 (en) 2015-10-23 2021-02-25 Apogenix Ag Single-chain CD27-receptor agonist proteins
WO2017102010A1 (en) * 2015-12-17 2017-06-22 Biontech Rna Pharmaceuticals Gmbh Novel cytokine fusion proteins
CN109153711B (zh) * 2016-03-01 2022-04-26 伊利诺伊大学理事会 具有降低的l-谷氨酰胺酶活性和增强的稳定性的l-天冬酰胺酶变体和融合蛋白
MX2018011219A (es) * 2016-03-16 2019-01-10 Merrimack Pharmaceuticals Inc Trail diseñado por ingenieria para terapia de cancer.
US10501744B2 (en) 2016-05-04 2019-12-10 Indiana University Research And Technology Corporation Presentation of bioactive proteins
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
CN109641033A (zh) * 2016-06-13 2019-04-16 梅里麦克制药股份有限公司 用基于trail的治疗剂或死亡受体激动剂选择和治疗患者的方法
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
CA3106549A1 (en) * 2017-08-11 2019-02-14 The Board Of Trustees Of The University Of Illinois Truncated guinea pig l-asparaginase variants and methods of use
WO2019178438A1 (en) 2018-03-15 2019-09-19 Abbvie Inc. Abbv-621 in combination with anti-cancer agents for the treatment of cancer
WO2019178433A1 (en) 2018-03-15 2019-09-19 Abbvie Inc. Abbv-621 in combination with anti-cancer agents for the treatment of pancreatic cancer
EP4149964A2 (en) 2020-05-15 2023-03-22 Apogenix AG Multi-specific immune modulators
WO2022248662A1 (en) 2021-05-28 2022-12-01 Julius-Maximilians-Universität Würzburg Recombinant proteinaceous binding molecules
WO2023088876A1 (en) 2021-11-16 2023-05-25 Apogenix Ag Multi-specific immune modulators

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7645700A (en) 1999-10-07 2001-05-10 Maxygen Aps Single-chain antagonist polypeptides
DE19963859A1 (de) 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
CA2314199A1 (en) 2000-07-21 2002-01-21 Robert Simoneau C-chip
MXPA03005036A (es) 2000-12-07 2003-09-05 Lilly Co Eli Proteinas de fusion glp-1.
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7538088B2 (en) 2002-04-26 2009-05-26 California Institute Of Technology Method for inhibiting angiogenesis by administration of the extracellular domain of D1-1 polypeptide
DE102004014983A1 (de) 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
US20060188498A1 (en) * 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
US8388962B2 (en) * 2005-04-15 2013-03-05 Rappaport Family Institute For Research In The Medical Sciences Molecules and methods of using same for treating MCP-1/CCR2 associated diseases
CA2606102C (en) 2005-04-26 2014-09-30 Medimmune, Inc. Modulation of antibody effector function by hinge domain engineering
EP1894940A1 (en) 2006-08-28 2008-03-05 Apogenix GmbH TNF superfamily fusion proteins
EP2176288B1 (en) 2007-07-10 2015-11-04 Apogenix GmbH Tnf superfamily collectin fusion proteins
BRPI0913406A2 (pt) 2008-06-03 2018-01-09 Abbott Lab imunoglobulinas de domínio variável duplo e usos das mesmas
EP2310509B1 (en) * 2008-07-21 2015-01-21 Apogenix GmbH Tnfsf single chain molecules
US20110287001A1 (en) 2008-09-22 2011-11-24 Tetralogic Pharmaceuticals Method of treatment
EP2379585A2 (en) * 2008-10-10 2011-10-26 Anaphore, Inc. Polypeptides that bind trail-ri and trail-r2
ES2593049T3 (es) 2009-01-09 2016-12-05 Apogenix Ag Proteínas de fusión que forman trímeros
CA2750533A1 (en) * 2009-01-23 2010-07-29 Biogen Idec Ma Inc. Stabilized fc polypeptides with reduced effector function and methods of use
EP2516458A1 (en) 2009-12-22 2012-10-31 Novartis AG Tetravalent cd47-antibody constant region fusion protein for use in therapy
CA2795325A1 (en) * 2010-04-13 2011-10-20 Medimmune, Llc Fibronectin type iii domain-based multimeric scaffolds
US9764038B2 (en) * 2011-12-23 2017-09-19 Innate Pharma Enzymatic conjugation of antibodies
CN104640876A (zh) * 2012-07-18 2015-05-20 阿珀吉尼科斯有限公司 包含CD95-Fc同种型的混合物的组合物

Also Published As

Publication number Publication date
CA2946402C (en) 2023-02-28
DK3134430T3 (en) 2018-05-22
HUE038914T2 (hu) 2018-12-28
UY36095A (es) 2015-10-30
AR100168A1 (es) 2016-09-14
PE20170299A1 (es) 2017-05-06
SG10201806465TA (en) 2018-08-30
PL3134430T3 (pl) 2018-08-31
IL272612A (en) 2020-03-31
TWI683825B (zh) 2020-02-01
SI3134430T1 (en) 2018-05-31
PH12016502079A1 (en) 2016-12-19
CL2016002683A1 (es) 2017-07-07
UA118286C2 (uk) 2018-12-26
TW202024123A (zh) 2020-07-01
AU2015249649A1 (en) 2016-11-10
TWI747178B (zh) 2021-11-21
RU2016145608A3 (pt) 2018-12-26
US20210040178A1 (en) 2021-02-11
US20180222962A1 (en) 2018-08-09
TW201620928A (zh) 2016-06-16
IL248244B (en) 2020-03-31
CN106459221B (zh) 2020-09-01
MX2016013858A (es) 2017-08-02
AU2018271369A1 (en) 2018-12-20
JP6714751B2 (ja) 2020-06-24
MY181986A (en) 2021-01-18
WO2015164588A1 (en) 2015-10-29
EP3134430A1 (en) 2017-03-01
CR20160516A (es) 2017-05-10
CY1120281T1 (el) 2019-07-10
KR20190135546A (ko) 2019-12-06
PH12016502079B1 (en) 2016-12-19
EP3366699A1 (en) 2018-08-29
SG11201608767XA (en) 2016-11-29
MX2019013587A (es) 2020-01-13
US20150337027A1 (en) 2015-11-26
MA39770A (fr) 2015-10-29
IL248244A0 (en) 2016-11-30
SG10202111785VA (en) 2021-12-30
HRP20180950T1 (hr) 2018-08-10
JP2019162114A (ja) 2019-09-26
MA45069A (fr) 2019-04-03
BR112016024515B1 (pt) 2020-03-31
TR201806912T4 (tr) 2018-06-21
NZ725476A (en) 2023-09-29
JP2017513503A (ja) 2017-06-01
RU2699285C2 (ru) 2019-09-04
US9908927B2 (en) 2018-03-06
AU2020202247A1 (en) 2020-04-23
RU2016145608A (ru) 2018-05-28
JP6523331B2 (ja) 2019-05-29
ECSP16089579A (es) 2018-05-31
NO2776305T3 (pt) 2018-01-27
LT3134430T (lt) 2018-05-10
KR20170012257A (ko) 2017-02-02
AU2015249649B2 (en) 2018-10-04
US20240174731A1 (en) 2024-05-30
ES2672368T3 (es) 2018-06-14
BR112016024515A2 (pt) 2017-10-10
CA3184067A1 (en) 2015-10-29
CN106459221A (zh) 2017-02-22
KR102079919B1 (ko) 2020-02-24
CA2946402A1 (en) 2015-10-29
AU2018271369B2 (en) 2020-01-02
CN111718424A (zh) 2020-09-29
RS57153B1 (sr) 2018-07-31
DOP2016000284A (es) 2017-02-15
EP3134430B1 (en) 2018-03-21

Similar Documents

Publication Publication Date Title
IL272612A (en) Single-chain proteins are agonists of the TRAIL receptor
HK1232136A1 (zh) 融合蛋白
SG11201704010UA (en) Fibroin-derived protein composition
PL3702450T3 (pl) Białko
GB201415344D0 (en) Protein
GB201515745D0 (en) Proteins
GB201511787D0 (en) Proteins
IL250502B (en) New polypeptides
IL248276A0 (en) Carbohydrate binding proteins
PL3099793T3 (pl) Białko
GB201513033D0 (en) Proteins
SG11201606501PA (en) Nanobody-fluorescent protein fusion
GB201517390D0 (en) Protein variant analysis
GB201504048D0 (en) Material sampler
GB201412797D0 (en) Proteins
GB201412646D0 (en) Proteins
GB201412648D0 (en) Proteins
GB201412649D0 (en) Proteins
GB201406894D0 (en) Proteins
GB201515744D0 (en) Proteins
GB201405952D0 (en) Proteins
GB201405955D0 (en) Proteins
GB201403912D0 (en) Proteins
GB201403914D0 (en) Proteins
GB201403915D0 (en) Proteins